Related Experiment Video
Updated: May 13, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Targeting interleukin-6 in rheumatoid arthritis
Md Yuzaiful Md Yusof1, Paul Emery
1Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals, Leeds, UK.
Drugs
|March 5, 2013
Summary
Interleukin-6 (IL-6) inhibitors, like tocilizumab, show comparable efficacy to other biologics for rheumatoid arthritis (RA) treatment. IL-6 blockade offers a unique therapeutic approach for RA, particularly effective as monotherapy.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Interleukin-6 (IL-6) is a key pro-inflammatory cytokine driving systemic inflammation and joint destruction in rheumatoid arthritis (RA).
- Targeting the IL-6 pathway presents a promising therapeutic strategy for managing RA's complex pathogenesis.
- Tocilizumab, an IL-6 receptor inhibitor, is currently approved for moderate to severe RA and systemic juvenile idiopathic arthritis (JIA).
Purpose of the Study:
- To provide an updated analysis of the clinical efficacy and tolerability of IL-6 inhibitors in RA treatment.
- To evaluate the comparative effectiveness of tocilizumab against existing RA therapies.
- To identify patient subgroups most likely to benefit from IL-6 inhibition.
Main Methods:
- Review of clinical trial data for tocilizumab and other IL-6 blocking agents.
- Analysis of efficacy endpoints including physical function, radiographic progression, and systemic manifestations.
- Assessment of safety profiles, including adverse events and tolerability in diverse patient populations.
Main Results:
- Tocilizumab demonstrates clinical efficacy comparable to other RA biologics, improving physical function and halting radiographic progression.
- IL-6 inhibition is particularly beneficial for RA patients with systemic features like high inflammatory markers and anemia.
- Tocilizumab shows superiority over methotrexate in head-to-head studies and is effective as monotherapy, offering an alternative for patients intolerant to combination therapy.
Conclusions:
- IL-6 blockade represents a significant advancement in RA treatment, targeting a unique inflammatory mediator.
- Tocilizumab exhibits a comparable safety profile to other biologics, though increased infections are noted in elderly patients and those with comorbidities.
- Long-term cardiovascular safety and efficacy data for subcutaneous IL-6 inhibitors are anticipated in the coming years.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...